News

Company News & Events

ORYZON Closes € 5.3 Million (6 M USD) in additional Debt Financing

26 September 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

• With these funds the company completes its Global Funding of € 32 Million (36 Million USD)

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has closed a second tranche of Debt Funding round of 5.3 Million Euros (5.9 Million USD). These proceeds come on top of the 10.5 Million Euros (11.6 Million USD) raised in May.In total, Oryzon have raised more than 32 Million Euros (35.5 Million USD) since July 2015.

Click here to see the full Press Release

Posted In: 
Investors
News

Share this story